Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications - - Management to host webcast and conference call...
-
- Oncolytic virus enhances immune checkpoint inhibitor response in prostate cancers - CALGARY, Alberta and SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX:...
-
CALGARY, Alberta and SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic...
-
Pelareorep ideal candidate for combination with immune checkpoint inhibitors CALGARY, Alberta and SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC),...
-
CALGARY, Alberta and SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic...
-
- Pelareorep more than doubles overall survival at recommended phase two dose as compared to historical phase 3 data - CALGARY, Alberta and SAN DIEGO, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Oncolytics...
-
- Pelareorep and FOLFIRI/B combination shows superior OS & PFS data in KRAS mutant colorectal cancer compared to historical data - CALGARY, Alberta and SAN DIEGO, Oct. 11, 2018 (GLOBE NEWSWIRE)...
-
CALGARY, Alberta and SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic...
-
CALGARY, Alberta and SAN DIEGO, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY), (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic...
-
CALGARY, Alberta and SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing pelareorep, an intravenously delivered immuno-oncolytic...